We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00282399
First Posted: January 26, 2006
Last Update Posted: October 28, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eisai Inc.
  Purpose
The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).

Condition Intervention Phase
Myelodysplastic Syndrome Drug: Subcutaneous Decitabine Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Phase I: To determine which of the subcutaneous (SQ) doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS. [ Time Frame: Up to 8 cycles (224 days) ]
  • Phase II: To evaluate hematological response at the dose selected in the Phase I portion of the study. [ Time Frame: Up to 12 cycles (336 days) ]

Enrollment: 41
Study Start Date: October 2006
Study Completion Date: February 2009
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DACO-019 2mg/m^2
DACO-019 2mg/m^2 twice daily (BID)
Drug: Subcutaneous Decitabine
Experimental: DACO-019 5mg/m^2
DACO-019 5mg/m^2 BID
Drug: Subcutaneous Decitabine
Experimental: DACO-019 10mg/m^2
DACO-019 10mg/m^2 BID
Drug: Subcutaneous Decitabine

Detailed Description:

Phase I: The purpose of this study was to determine which of the subcutaneous doses of decitabine administered twice daily for 5 days maximizes genomic demethylation in patients with MDS

Phase II: To evaluate hematological responses at the dose selected in the Phase I portion of the study.

Note: This study was planned as Phase 1/2 study but only the Phase 1 part was conducted due to a change in product development strategy

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
  2. Confirmed diagnosis of MDS or non-proliferative chronic myelomonocytic leukemia (CMML).

Exclusion Criteria:

  1. Prior therapy with decitabine or azacytidine (Vidaza).
  2. Experimental or standard drugs for the treatment of MDS within 28 days of the first day of study drug treatment.
  3. Clinically significant anemia.
  4. Prior history of malignancy other than MDS.
  5. Any active infection.
  6. Radiotherapy within 14 days prior to study enrollment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00282399


Locations
United States, Arizona
University of Arizona Cancer Center
Tucson, Arizona, United States, 85724
United States, Florida
H Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, New York
Albert Einstein College of Medicine
Bronx, New York, United States, 10461
Sponsors and Collaborators
Eisai Inc.
  More Information

Additional Information:
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00282399     History of Changes
Other Study ID Numbers: DACO-019
First Submitted: January 25, 2006
First Posted: January 26, 2006
Last Update Posted: October 28, 2015
Last Verified: October 2015

Keywords provided by Eisai Inc.:
Myelodysplastic Syndrome
MGI Pharma
Decitabine
Dacogen

Additional relevant MeSH terms:
Syndrome
Myelodysplastic Syndromes
Preleukemia
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms
Decitabine
Azacitidine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors